MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT02293980A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · ccRCCActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02974738A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Advanced Solid TumorsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 12, 2018Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT07748351A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Dec 15, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07776665A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell...Merck Sharp & Dohme LLC · Renal Cell CarcinomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Dec 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04184050Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Multiple Myeloma in RelapseActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06688058A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Merck Sharp & Dohme LLC · Carcinoma, Renal CellActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Feb 2, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Merck Sharp & Dohme LLC · Hodgkin LymphomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Feb 12, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06099782A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over...Merck Sharp & Dohme LLC · Non-Small Cell Lung CancerActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Apr 9, 2025Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.